CSIMarket Company Name, Ticker, Competitors, else..
 
Nevro Corp   (NYSE: NVRO)
Other Ticker:  
 
 
Price: $4.5700 $0.07 1.556%
Day's High: $4.66 Week Perf: 13.4 %
Day's Low: $ 4.44 30 Day Perf: 10.12 %
Volume (M): 389 52 Wk High: $ 19.47
Volume (M$): $ 1,777 52 Wk Avg: $8.92
Open: $4.60 52 Wk Low: $3.17



 Market Capitalization (Millions $) 171
 Shares Outstanding (Millions) 37
 Employees 1,215
 Revenues (TTM) (Millions $) 418
 Net Income (TTM) (Millions $) -69
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) 10

Nevro Corp
Nevro Corp is a medical technology company that specializes in the development and commercialization of innovative spinal cord stimulation therapies for patients suffering from chronic pain. The company was founded in 2006 and is headquartered in Redwood City, California. Nevro's flagship product is the Senza system, which uses high-frequency spinal cord stimulation to provide long-lasting pain relief to patients.

The Senza system works by delivering electrical pulses to the nerve fibers in the spinal cord, which disrupt the pain signals that are being sent from the affected area of the body to the brain. This results in significant and sustained relief from chronic pain, without the need for opioids or other potentially addictive medications. The Senza system is designed to be highly customizable to the individual patient's needs, with a range of different stimulation options and programming settings available.

Nevro has a strong commitment to research and development, with a dedicated team working to continually improve the Senza system and explore new approaches to pain management. The company has invested heavily in large-scale clinical trials to demonstrate the safety and effectiveness of its technology, and has published numerous peer-reviewed studies in leading medical journals.

In addition to the Senza system, Nevro offers a range of related products and services, including training and support for healthcare providers, patient education resources, and clinical research collaboration opportunities. The company has a global presence, with operations in Europe, Asia-Pacific, and North America, and is actively expanding its reach into new markets and treatment areas.

Overall, Nevro Corp is a pioneering medical technology company that is making a major impact in the field of pain management. With its innovative spinal cord stimulation technology, commitment to research and development, and global reach, Nevro is a leading player in this fast-growing market.


   Company Address: 1800 Bridge Parkway Redwood City 94065 CA
   Company Phone Number: 251-0005   Stock Exchange / Ticker: NYSE NVRO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AXNX        0.8% 
BSX        4.28% 
INSP        1.28% 
MDT        7.69% 
SYK        6.22% 
TCMD        1.16% 
• View Complete Report
   



Stocks on the Move

Market Sentiment Sours Decoding Nevro Corps Stock Sell-Off Amid Financial Struggles,

Published Thu, Aug 8 2024 3:19 PM UTC

In recent trading sessions, Nevro Corp (NYSE: NVRO) has experienced a noticeable decline, trailing behind broader market performance. This sell-off can be attributed to a confluence of analyst downgrades, disappointing financial results, and strategic uncertainties that raise concerns among investors. As Nevro navigates this turbulent landscape, understanding the undercurren...
Nevro Corp

Nevro Corp Faces Challenges in Q3 2023, but Revenue Sees Slight Improvement2.

Over the past 5 days, shares of Nevro Corp, a medical equipment and supplies company, have seen a significant drop of -7.97%. This decline has brought the year to date performance to -63.65%, reaching its lowest point in the past 52 weeks.
Looking at the financial performance of Nevro Corp, it is evident that the company faced challenges in the third quarter of 2023. During this period, the company experienced a net loss per share of $-0.65, a considerable contrast compared to the $2.22 per share profit recorded a year earlier. However, there was a slight increase in revenue, which saw a growth of 3.036% to $103.52 million compared to the same period last year.
Nevro Corp

Nevro Corp Defies Industry Norms with 4.41% Q2 Monetary Boost, Questioning the Adequacy Amid Financial Turbulence

Nevro Corp, a medical technology company that specializes in the development and manufacturing of innovative spinal cord stimulation systems, recently released its financial results for the second quarter of 2023. The company's performance during this period showcased a decrease in loss per share, an improvement in income per share, and a modest increase in revenue.
Compared to the same period the previous year, Nevro Corp managed to decrease its loss per share from $-0.71 to $-0.69 per share. Additionally, the company saw an improvement in its income per share, which increased from $-0.98 to $-0.69 per share when compared to the preceding reporting period. These numbers indicate that Nevro Corp is making strides towards profitability.






Nevro's Segments
United States    86.84 % of total Revenue
International    13.47 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com